Krystal Biotech (NASDAQ:KRYS) Announces Quarterly Earnings Results

Krystal Biotech (NASDAQ:KRYS) released its earnings results on Monday. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.20 by ($0.17), Briefing.com reports. The company had revenue of $45.25 million during the quarter, compared to analysts’ expectations of $47.37 million. Krystal Biotech’s quarterly revenue was up 452400.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.76) earnings per share.

Krystal Biotech Stock Up 0.4 %

Shares of KRYS traded up $0.69 during mid-day trading on Thursday, reaching $158.37. 4,889 shares of the company’s stock were exchanged, compared to its average volume of 359,831. Krystal Biotech has a 52-week low of $86.03 and a 52-week high of $189.97. The company has a 50-day simple moving average of $168.76 and a two-hundred day simple moving average of $134.27. The company has a market cap of $4.52 billion, a price-to-earnings ratio of 1,971.25 and a beta of 0.91.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Stifel Nicolaus reiterated a “buy” rating and issued a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Citigroup upped their price target on Krystal Biotech from $160.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Guggenheim increased their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a research report on Monday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Krystal Biotech has an average rating of “Buy” and a consensus target price of $171.00.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the completion of the transaction, the insider now owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now directly owns 1,550,882 shares of the company’s stock, valued at approximately $265,138,786.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CAO Kathryn Romano sold 5,000 shares of the company’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total transaction of $829,400.00. Following the transaction, the chief accounting officer now directly owns 12,936 shares of the company’s stock, valued at approximately $2,145,823.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 38,087 shares of company stock valued at $6,210,591. Corporate insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).